Login to Your Account

Gilead, Galapagos crank FINCH phase III; Abbvie in 'passerine' lane

By Randy Osborne
Staff Writer

Tuesday, August 23, 2016

In September 2015, when Galapagos NV lost its partnership with Abbvie Inc. for JAK 1 inhibitor filgotinib in RA – but kept intact their agreement for CF – the search for a new tie-up began right away.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription